Charles Reay Mackay joins Pfizer
This article was originally published in Scrip
Executive Summary
Pfizer has named Charles Reay Mackay chief scientific officer for its inflammation and immunology research unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, group vice-president of BioTherapeutics R&D, and will be based in Pfizer's R&D hub in Cambridge, Massachusetts. Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was chair of diabetes. Inflammation and immunology is one of Pfizer's key therapeutic areas.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.